ATE356130T1 - Inhibitoren von cruzipain und anderen cysteinproteasen - Google Patents

Inhibitoren von cruzipain und anderen cysteinproteasen

Info

Publication number
ATE356130T1
ATE356130T1 AT02732145T AT02732145T ATE356130T1 AT E356130 T1 ATE356130 T1 AT E356130T1 AT 02732145 T AT02732145 T AT 02732145T AT 02732145 T AT02732145 T AT 02732145T AT E356130 T1 ATE356130 T1 AT E356130T1
Authority
AT
Austria
Prior art keywords
inhibitors
cruzipain
cysteine proteases
general formula
compounds
Prior art date
Application number
AT02732145T
Other languages
English (en)
Inventor
Martin Quibell
Original Assignee
Amura Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0101179A external-priority patent/GB0101179D0/en
Application filed by Amura Therapeutics Ltd filed Critical Amura Therapeutics Ltd
Application granted granted Critical
Publication of ATE356130T1 publication Critical patent/ATE356130T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT02732145T 2001-01-17 2002-01-17 Inhibitoren von cruzipain und anderen cysteinproteasen ATE356130T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0101179A GB0101179D0 (en) 2001-01-17 2001-01-17 Biologically active compounds
US27535901P 2001-03-13 2001-03-13

Publications (1)

Publication Number Publication Date
ATE356130T1 true ATE356130T1 (de) 2007-03-15

Family

ID=26245571

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02732145T ATE356130T1 (de) 2001-01-17 2002-01-17 Inhibitoren von cruzipain und anderen cysteinproteasen

Country Status (20)

Country Link
US (2) US7425562B2 (de)
EP (1) EP1362052B1 (de)
JP (1) JP4608183B2 (de)
KR (1) KR100860067B1 (de)
CN (1) CN1269822C (de)
AT (1) ATE356130T1 (de)
AU (1) AU2002219397B2 (de)
BR (1) BR0206501A (de)
CA (1) CA2436462C (de)
CY (1) CY1106640T1 (de)
DE (1) DE60218633T2 (de)
DK (1) DK1362052T3 (de)
ES (1) ES2281516T3 (de)
IL (2) IL156774A0 (de)
MX (1) MXPA03006224A (de)
NO (1) NO328208B1 (de)
NZ (1) NZ526913A (de)
PT (1) PT1362052E (de)
RU (1) RU2329266C2 (de)
WO (1) WO2002057270A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL156577A0 (en) 2000-12-22 2004-01-04 Axys Pharm Inc Selective cathepsin s inhibitors and pharmaceutical compositions containing the same
US7030116B2 (en) 2000-12-22 2006-04-18 Aventis Pharmaceuticals Inc. Compounds and compositions as cathepsin inhibitors
WO2003024924A1 (en) 2001-09-14 2003-03-27 Aventis Pharmaceuticals Inc. Novel compounds and compositions as cathepsin inhibitors
RU2004117877A (ru) 2001-11-14 2006-01-10 Авентис Фармасьютикалз Инк. (Us) Олигопептиды и композиции, содержащие их, в качестве ингибиторов катепсина s
JP2006504651A (ja) * 2002-07-16 2006-02-09 アミュラ テラピューティクス リミテッド 生物活性化合物
US7399765B2 (en) * 2003-09-19 2008-07-15 Abbott Laboratories Substituted diazabicycloalkane derivatives
SE0400022D0 (sv) * 2004-01-08 2004-01-08 Medivir Ab New compounds
US7915300B2 (en) * 2004-01-08 2011-03-29 Medivir Ab Cysteine protease inhibitors
JP2005350417A (ja) * 2004-06-11 2005-12-22 Dai Ichi Seiyaku Co Ltd 還元的エーテル化法を用いたピロリジン誘導体の製造法
DK1865940T3 (da) * 2005-03-21 2013-03-04 Virobay Inc Alfaketoamidforbindelser som cysteinproteasehæmmere
GB0513840D0 (en) * 2005-07-07 2005-08-10 Medivir Ab Cysteine protease inhibitors
GB0513839D0 (en) * 2005-07-07 2005-08-10 Medivir Ab Cysteine protease inhibitors
GB0614037D0 (en) 2006-07-14 2006-08-23 Amura Therapeutics Ltd Compounds
GB0614046D0 (en) 2006-07-14 2006-08-23 Amura Therapeutics Ltd Compounds
GB0614053D0 (en) * 2006-07-14 2006-08-23 Amura Therapeutics Ltd Compounds
GB0614073D0 (en) 2006-07-14 2006-08-23 Amura Therapeutics Ltd Compounds
GB0614052D0 (en) * 2006-07-14 2006-08-23 Amura Therapeutics Ltd Compounds
GB0614044D0 (en) 2006-07-14 2006-08-23 Amura Therapeutics Ltd Compounds
GB0614042D0 (en) 2006-07-14 2006-08-23 Amura Therapeutics Ltd Compounds
WO2008114054A1 (en) * 2007-03-19 2008-09-25 Medivir Ab Protease inhibitors
US7893067B2 (en) * 2007-06-27 2011-02-22 Medivir Ab Cysteine protease inhibitors
WO2009087379A2 (en) * 2008-01-09 2009-07-16 Amura Therapeutics Limited Tetrahydrofuro (3, 2 -b) pyrrol- 3 -one derivatives as inhibitors of cysteine proteinases
GB0804702D0 (en) * 2008-03-13 2008-04-16 Amura Therapeutics Ltd Compounds
GB0804701D0 (en) * 2008-03-13 2008-04-16 Amura Therapeutics Ltd Compounds
WO2012099785A2 (en) 2011-01-20 2012-07-26 The Regents Of The University Of Colorado, A Body Corporate Modulators of tlr3/dsrna complex and uses thereof
CN106963760A (zh) * 2012-08-30 2017-07-21 国立大学法人东京大学 体内寄生虫防治剂在制备防治体内寄生虫的药物中的用途
CN106279188A (zh) * 2016-07-21 2017-01-04 青岛科技大学 一种多取代呋喃并[2,3‑b]吡咯衍生物的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3652574A (en) * 1970-04-01 1972-03-28 Abbott Lab Certain 1 2 3 4 - tetrahydro-5h-pyrido (4 3-b)indoles and the corresponding 1 2 3 4-tetrahydro-9h-pyrido(3 4-b)indoles and derivatives thereof
DE3601226A1 (de) * 1986-01-17 1987-07-23 Bayer Ag Dihydropyridinlactole, verfahren zur herstellung und ihre verwendung in arzneimitteln
RU2137768C1 (ru) * 1993-12-15 1999-09-20 Мерк энд Ко, Инк. Ингибиторы hiv протеазы
DZ2285A1 (fr) 1996-08-08 2002-12-25 Smithkline Beecham Corp Inhibiteurs de protéase de la cystéine.
EP0923535A4 (de) 1996-08-28 2001-01-10 Smithkline Beecham Corp Inhibitoren der cystein-protease
HRP970705A2 (en) 1996-12-23 1998-10-31 Warren J. Porter CYCLOALKYL, LACTAM, LACTONE AND RELATED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING "beta" -AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS
AR013079A1 (es) * 1997-05-06 2000-12-13 Smithkline Beecham Corp Derivados sustituidos de tetrahidrofurano-3-onas, de tetrahidropirano-3- onas y tetrahidrotiofen-3-onas, un procedimiento para su preparacion unacomposicion farmaceutica de un medicamento util como inhibidores de proteasas e intermediarios
MA26618A1 (fr) 1998-04-09 2004-12-20 Smithkline Beecham Corp Composes et compositions pharmaceutiques pour le traitement du paludisme
CO5150165A1 (es) 1998-11-13 2002-04-29 Smithkline Beecham Plc Inhibidores de proteasa: tipo catepsina k
GB9911417D0 (en) 1999-05-18 1999-07-14 Peptide Therapeutics Ltd Furanone derivatives as inhibitors of cathepsin s
AU2002227222A1 (en) 2000-11-17 2002-05-27 Genzyme Corporation Cysteine protease inhibitors
IL156577A0 (en) 2000-12-22 2004-01-04 Axys Pharm Inc Selective cathepsin s inhibitors and pharmaceutical compositions containing the same

Also Published As

Publication number Publication date
HK1060729A1 (en) 2004-08-20
CN1486320A (zh) 2004-03-31
CA2436462C (en) 2011-07-05
EP1362052A1 (de) 2003-11-19
NO20033220D0 (no) 2003-07-16
NO20033220L (no) 2003-09-17
WO2002057270A1 (en) 2002-07-25
US20040138250A1 (en) 2004-07-15
JP4608183B2 (ja) 2011-01-05
RU2329266C2 (ru) 2008-07-20
NZ526913A (en) 2004-12-24
JP2004518674A (ja) 2004-06-24
KR20030075161A (ko) 2003-09-22
DE60218633T2 (de) 2008-02-21
IL156774A0 (en) 2004-02-08
CN1269822C (zh) 2006-08-16
NO328208B1 (no) 2010-01-11
EP1362052B1 (de) 2007-03-07
US20090247471A1 (en) 2009-10-01
KR100860067B1 (ko) 2008-09-24
DK1362052T3 (da) 2007-07-09
IL156774A (en) 2008-08-07
PT1362052E (pt) 2007-04-30
RU2003125270A (ru) 2005-02-20
CA2436462A1 (en) 2002-07-25
US7425562B2 (en) 2008-09-16
ES2281516T3 (es) 2007-10-01
BR0206501A (pt) 2004-01-13
MXPA03006224A (es) 2004-10-15
CY1106640T1 (el) 2012-01-25
DE60218633D1 (de) 2007-04-19
AU2002219397B2 (en) 2008-02-14

Similar Documents

Publication Publication Date Title
DE60218633D1 (de) Inhibitoren von cruzipain und anderen cysteinproteasen
TR199901191T2 (xx) Benzamidoaldehitlerin sistein proteaz� inhibit�r� olarak kullan�m�.
BR0215405A (pt) Composições e processos de uso de collajolie
BR0111451A (pt) Inibidores de serina protease
EA200400648A1 (ru) N, n'-замещенные производные 1,3-диамино-2-гидроксипропана
SE0201976D0 (sv) Novel compounds
CY1114554T1 (el) Ινδαζολια, βενζοτριαζολια και ν-αναλογα αυτων ως αναστολεις p38 κινασης
BRPI0418251A (pt) fosfonatos, monofosfonamidatos, bisfosfonamidatos para o tratamento de doenças virais
SE0102315D0 (sv) Compounds
ATE454378T1 (de) Verbindungen, die sich als inhibitoren vonjak und anderen proteinkinasen eignen
PT1465864E (pt) Inibidores de factor xa e outras serina proteases envolvidos na cascata da coagulacao
DE60235083D1 (de) Substituierte tetracyclin-verbindungen zur behandlung von malaria
ATE443043T1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
BR0317715A (pt) Composições e processos de uso de collajolie
DE60237725D1 (de) Vervendung von dexrazoxane in der prävention und behandlung der alzeheimer-krankheit
EA200301100A1 (ru) Новые фталазиноны
ATE416157T1 (de) Inhibitoren von integrin alpha-v-beta-6
CY1108446T1 (el) Μη νευροτοξικοι παραγοντες ενεργοποιησης πλασμινογονου για την αντιμετωπιση αποπληξιας
ATE275544T1 (de) Serinprotease-inhibitoren
ATE303384T1 (de) 1-biaryl-1,8-naphthyridin-4-one als phosphodieseterase-inhibitoren
BR0116166A (pt) Inibidores da serina protease
SE0101932D0 (sv) Pharmaceutical combinations
DE60211132D1 (de) 2-alkylierte cyclodextrinderivate : umkehrungsmittel von medikament-induzierter neuromuskulärer blockierung
SE0101038D0 (sv) Novel compounds
SE0003476D0 (sv) Compounds

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1362052

Country of ref document: EP